Claims for Patent: 10,004,747

✉ Email this page to a colleague

Summary for Patent: 10,004,747

Title:	Combination therapy
Abstract:	The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
Inventor(s):	Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	15/428,594
Patent Claims:	1. A method for achieving a reduction in the dose of a GLP-1 receptor agonist required for reducing and maintaining body weight and/or body fat in an overweight or obesity patient with or without diabetes, said method comprising administering the GLP-1 receptor agonist in combination with linagliptin to the patient, wherein said administration is sequential administration of the GLP-1 receptor agonist in an amount effective to reduce body weight and/or body fat followed by linagliptin in an amount effective to maintain the reduced body weight and/or body fat. 2. The method according to claim 1, wherein the GLP-1 receptor agonist is selected from the group consisting of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide and dulaglutide. 3. The method according to claim 1, wherein the GLP-1 receptor agonist and linagliptin are present in separate dosage forms. 4. The method of claim 1, wherein the GLP-1 receptor agonist is exenatide.

Details for Patent 10,004,747

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014	10,004,747	2037-02-09
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014	10,004,747	2037-02-09
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 04, 2020	10,004,747	2037-02-09
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	July 27, 2016	10,004,747	2037-02-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.